Redalpine scores 10x exit from InSphero

The exit comes five years after Redalpine's first investment in the company, and three months after InSphero's CHF 20m series-C round. The company received the series-C funding from Wild Group Management, the investment vehicle of Capri-Sun owner Hans-Peter Wild.

Redalpine did not exit the business to Wild but to another undisclosed family office. The VC stated that since the series-C was heavily oversubscribed, it found the time ideal for a sale.

The Redalpine Capital I fund, which launched in 2007 and reached final close in 2008, is currently in the divestment phase. The vehicle exited Redbiotec in January 2015 when Pfizer bought the portfolio company's spin-off Redvax.

Company
Established in 2009 and currently employing 35 staff, InSphero develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compound screening and predictive drug testing applications. It is based in the US and in Zurich, Switzerland.

People
Jan Lichtenberg is the CEO and co-founder of InSphero. Michael Sidler is a founding partner at Redalpine.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Exits
• Healthcare
• Switzerland
• Venture